Business Of Biotech Bringing Curative Cell Therapies To Market with Kite Pharma's Cindy Perettie
Feb 9, 2026
Cindy Perettie, EVP and Global Head at Kite Pharma, veteran leader in oncology commercialization and cell-therapy scale-up. She talks about scaling cell therapies into community care. She covers global manufacturing strategy, preparing major lymphoma and myeloma launches, partnerships like Arcellx, autologous versus allogeneic approaches, in vivo CAR-T potential, and regulatory and funding dynamics.
AI Snips
Chapters
Transcript
Episode notes
Manufacturing And Authorized Centers Are Key
- Cell therapy launches require authorized treatment centers and robust manufacturing networks.
- Kite's turnaround times and 96% reliability are competitive advantages for timely patient treatment.
Make Therapies Outpatient-Ready
- Enable outpatient and community delivery by improving safety profiles and accreditation pathways.
- Work with accrediting bodies like FACT to unlock community practice access.
Kite–Arcellx Practical Partnership
- Kite co-promotes Anetacel with Arcellx in the U.S. and handles ex-U.S. commercialization.
- The partnership pairs Arcellx innovation with Kite's global development and manufacturing strengths.